Technology
Health
Pharmaceutical

Zynerba Pharmaceuticals

$12.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.19 (1.63%) Today
+$0.15 (1.26%) As of 6:13 PM EDT after-hours

Why Robinhood?

You can buy or sell ZYNE and other stocks, options, ETFs, and crypto commission-free!

About ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. Read More The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Employees
25
Headquarters
Devon, Pennsylvania
Founded
2007
Market Cap
246.16M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.67M
High Today
$12.24
Low Today
$11.50
Open Price
$11.95
Volume
1.39M
52 Week High
$16.47
52 Week Low
$2.75

Collections

Technology
Health
Pharmaceutical
Medical
2015 IPO
US
North America

ZYNE News

BenzingaJun 28

Canaccord Genuity Bullish On Zynerba Ahead Of CBD Gel Trial Data

7,355

ZYNE Earnings

-$0.91
-$0.75
-$0.60
-$0.44
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market

Popular Stocks

More ZYNE News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.